Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Discussion on RAINBOWFISH 2-year efficacy and safety data & the importance of newborn screening

Join Professor Laurent Servais, Advanced Nurse Practitioner Nicholas Mills, and Dr Anirban Majumdar as they discuss the clinical implications of the 2-year RAINBOWFISH data, and emphasise the critical role of newborn screening for infants with SMA.

 

  • Understand the implications of the 2-year RAINBOWFISH data to UK clinical practice
  • Explore how the safety profile and administration of Evrysdi impacts practice
  • Gain insights into the importance of newborn screening and current challenges in the UK

 

Please click on the magnify/search icon to jump to relevant chapters in the video.

Servais L. Presented at World Muscle Society congress. Prague, Czechia. 8–12 October 2024.

References

1. Evrysdi 5 mg film‑coated tablets Summary of Product Characteristics

2. Evrysdi 0.75 mg/mL powder for oral solution Summary of Product Characteristics
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.